United States – February 11, 2014 (PR Carbon): Reportstack has announced a new market report on MediPoint: Bone Grafts and Substitutes – Global Analysis and Market Forecasts. Bone grafting procedures are undergoing a gradual shift from autologous and allogeneic bone grafts to synthetic bone graft substitutes. The emergence of new biological or synthetic materials to facilitate regeneration of damaged or diseased bone can increasingly minimize the usage of autograft in the surgeries. In particular, the motivation to incorporate the favorable properties of different materials into an effective bone graft product has led to the manipulation and development of various new composite grafts. One of the recent attempts from orthopedic companies to enhance bone substitutes’ osteoconductivity is the incorporation of bioactive materials, such as bioactive glass. Meanwhile, with the increase in corporate and federal funding in regenerative medicine, stem cell therapies represent a fast-growing, high-margin opportunity. Today, some of the leading orthopedic companies have allocated a large portion of their R&D budget to these stem cell-based products.
A good example is the cell-based matrices recently introduced to the US market. The incorporation of adult mesenchymal stem cells into allograft bone gives rise to a matrix harnessing the healing triad – osteoconductivity, osteoinductivity, and osteogenesis. While evolution in bone graft materials is driven by the manufacturers, which create different bone substitutes products to enhance their product mix, it is mandatory that these advances be adequately studied in clinical practice. In a market that is inundated with biologics with very limited basic science data supporting the efficacy, availability of human clinical data to demonstrate product efficacy remains the key to success. The field of bone grafts and substitutes (BGS) is among the most promising markets in the orthopedic industry. In 2013, revenue from the global BGS market, consisting of traditional allograft bone, machined allograft bone, growth factors/bone morphogenetic proteins, demineralized bone matrices, synthetic bone substitutes, and cell-based matrices, is estimated to be $2,089.5m across the 10 major markets covered in this report. Despite the FDA’s ongoing scrutiny of the growth factor/BMP and cell-based matrices segments, the BGS market sales are expected to rise steadily, reaching $2,708.7m by 2020 with a CAGR of 3.8%.
Key Questions Answered
- Given the negative media literature surrounding Medtronic’s INFUSE Bone Graft, surgeons now hold varied opinions regarding the BMP products. How will the overall BGS market evolve following the continuing revenue decline in the BMP/growth factor segment?
- As health executives are scrutinizing purchases and using multiple channels to procure biologics at highly competitive prices, surgeon’s preference is no longer considered the top priority in many hospitals’ decision-making process. How are governments’ cost-containment measures affecting the utilization of different types of BGS products?
- Cell-based matrices have received increased enthusiasm in the US market. Yet ongoing scrutiny of the segment may have a negative impact on future growth of this segment. Will the cell-based matrices segment benefit from declining utilization of BMP/growth factor products?
More details and table of contents for this report can be found by visiting Bone Grafts and Substitutes – Global Analysis and Market Forecasts report.
Contact:
Debora White
Email: debora@reportstack.com
Ph: +1-888-789-6604
Help employers find you! Check out all the jobs and post your resume.
